In IDA-301, the overall rate of reported adverse events was higher in the ferumoxytol group than in the placebo group, although no new safety signals, outside of those described in the current Feraheme® (ferumoxytol) label, were observed in this study. The overall rate of serious adverse events (SAEs) was comparable between the two treatment groups, and two related SAEs of hypersensitivity, including one anaphylactic reaction, were reported in ferumoxytol-treated patients.
The patient-reported outcomes data are being presented in an oral presentation today at the ASH annual meeting. The safety and efficacy data from IDA-301 were presented in a poster session on Sunday, December 9, 2012 at the ASH annual meeting.
IDA-302 Study and Results
IDA-302 was a multicenter, open-label, active-controlled, international clinical trial designed to compare treatment between ferumoxytol and iron sucrose. Subjects were randomized 2:1 to receive a one gram IV course of either ferumoxytol (n=406) or iron sucrose (n=199), and the demographics and all baseline parameters were well balanced between the two treatment groups. The primary efficacy endpoint for U.S. regulators is the proportion of subjects who achieved a ≥ 2.0 g/dL increase in hemoglobin at any time from baseline to week 5; the primary efficacy endpoint for E.U. regulators is the mean change in hemoglobin from baseline to week 5.In the IDA-302 trial, ferumoxytol achieved both primary efficacy endpoints. Subjects treated with ferumoxytol achieved a significantly greater mean increase in hemoglobin of 2.7 g/dL at week 5, compared to a 2.4 g/dL increase for those treated with iron sucrose (p<0.013). By week 5, 84% of ferumoxytol-treated subjects achieved a ≥ 2.0 g/dL increase in hemoglobin, compared to 81% of those treated with iron sucrose. The overall rates of adverse events and related adverse events were comparable in ferumoxytol- and iron sucrose-treated subjects, and included many attributable to comorbid disease. However, the overall rate of SAEs, both related and unrelated as assessed by the investigator, was higher in ferumoxytol-treated subjects. The SAEs in two ferumoxytol-treated subjects were reported as related to the study drug by the investigators; these included one anaphylactoid reaction and one case of hypertension. In this study, no new safety signals, outside of those described in the current Feraheme® (ferumoxytol) label, were identified.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV